Claims for Patent: 8,859,741

Summary for Patent: 8,859,741

Title:	Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
Abstract:	Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
Inventor(s):	Jackson; Simon Mark (San Carlos, CA), Walker; Nigel Pelham Clinton (Burlingame, CA), Piper; Derek Evan (Santa Clara, CA), Shen; Wenyan (Palo Alto, CA), King; Chadwick Terence (North Vancouver, CA), Ketchem; Randal Robert (Snohomish, WA), Mehlin; Christopher (Seattle, WA), Carabeo; Teresa Arazas (New York, NY)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	14/261,087
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,859,741
Patent Claims:	1. An isolated monoclonal antibody that binds to PCSK9, wherein the isolated monoclonal antibody binds an epitope on PCSK9 comprising at least one of residues 237 or 238 of SEQ ID NO: 3, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR. 2. The isolated monoclonal antibody of claim 1, wherein the isolated monoclonal antibody is a neutralizing antibody. 3. The isolated monoclonal antibody of claim 2, wherein the isolated monoclonal antibody was produced by a CHO cell. 4. The isolated monoclonal antibody of claim 3, wherein the isolated monoclonal antibody binds to PCSK9 with a K.sub.D of less than or equal to 5.times.10.sup.-9 M. 5. The isolated monoclonal antibody of claim 2, wherein the isolated monoclonal antibody is a human antibody. 6. The isolated monoclonal antibody of claim 5, wherein the isolated monoclonal antibody comprises a light chain region that comprises an amino acid sequence of SEQ ID NO: 157. 7. The isolated monoclonal antibody of claim 2, wherein the epitope is a functional epitope. 8. The isolated monoclonal antibody of claim 2, wherein the epitope is a structural epitope. 9. The isolated monoclonal antibody of claim 2, wherein the epitope is an epitope on a native PCSK9 protein. 10. The isolated monoclonal antibody of claim 2, wherein the epitope comprises at least residue 237 of SEQ ID NO: 3. 11. The isolated monoclonal antibody of claim 2, wherein the epitope comprises at least residue 238 of SEQ ID NO: 3. 12. The isolated monoclonal antibody of claim 2, wherein the isolated monoclonal antibody is a humanized antibody. 13. An isolated monoclonal antibody that binds to human PCSK9 at one or more of amino acid residues 237 or 238 of SEQ ID NO: 3, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR. 14. The isolated monoclonal antibody of claim 13, wherein the isolated monoclonal antibody is a neutralizing antibody. 15. The isolated monoclonal antibody of claim 14, wherein the isolated monoclonal antibody was produced by a CHO cell. 16. The isolated monoclonal antibody of claim 15, wherein the isolated monoclonal antibody binds to PCSK9 with a K.sub.D of less than or equal to 5.times.10.sup.-9 M. 17. The isolated monoclonal antibody of claim 14, wherein the isolated monoclonal antibody is a human antibody. 18. The isolated monoclonal antibody of claim 17, wherein the isolated monoclonal antibody comprises a light chain region that comprises an amino acid sequence of SEQ ID NO: 157. 19. The isolated monoclonal antibody of claim 17, wherein the isolated monoclonal antibody further binds at least one of amino acid residues 153, 194, 374, 377, or 379 of SEQ ID NO: 3. 20. The isolated monoclonal antibody of claim 17, wherein the isolated monoclonal antibody further binds at least one of amino acid residues 367 or 382 of SEQ ID NO: 3. 21. The isolated monoclonal antibody of claim 17, wherein the isolated monoclonal antibody further binds at least one of amino acid residues 192, 194, or 197 of SEQ ID NO: 3. 22. The isolated monoclonal antibody of claim 14, wherein the isolated monoclonal antibody is a humanized antibody. 23. The isolated monoclonal antibody of claim 14, wherein the isolated monoclonal antibody binds at least amino acid residue 237 of SEQ ID NO: 3. 24. The isolated monoclonal antibody of claim 14, wherein the isolated monoclonal antibody binds at least amino acid residue 238 of SEQ ID NO: 3.

Details for Patent 8,859,741

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	REPATHA	evolocumab	Injection	125522	08/27/2015		2027-08-23
Amgen, Inc.	REPATHA	evolocumab	Injection	125522	07/08/2016		2027-08-23

International Patent Family for US Patent 8,859,741

Country	Patent Number	Estimated Expiration
Argentina	068011
Argentina	110799
Australia	2008288791
Australia	2013203677